Recombinant Human IFN-gamma

IFN-gamma (IFNγ), a class II interferon, activates macrophages and induces the expression of MHC I, MHC II, and co-activating molecules on antigen-presenting cells (APCs). IFN-gamma also can induce changes in the expression of proteasomes, thus enhancing antigen presentation. IFN-gamma also promotes the differentiation of CD4+ T cells to Th1 and inhibits the IL-4-dependent switching of B cell isotypes. IFN-gamma activates the JAK-STAT cellular pathway by phosphorylating JAK1 and JAK2 proteins. The immunomodulatory effect of interferon is manifested in its effects on the activity of host immune cells, such as macrophages, T cells, B cells, and NK cells. (1) IFN-gamma can increase the expression of MHC class II molecules on the surface of macrophages and enhance their antigen presentation ability; it also can upregulate macrophage Fc receptors to promote macrophage phagocytosis of immune complexes, antibody-coated pathogens, and tumor cells. (2) IFN-gamma promotes the differentiation of B cells and CD8+ T cells, rather than their proliferation. It can enhance the activity of TH1 cells, thus improving their cellular immune function. (3) IFN-gamma also has wide effects on other cells, including i) stimulating neutrophils and enhancing their phagocytosis; ii) activating NK cells and enhancing their cytotoxicity; and iii) stimulating the expression of MHC class II molecules on the cells where MHC class II molecules are not normally expressed (such as vascular endothelial cells, some epithelial cells and connective tissue cells), thus playing the role of antigen presentation. Recombinant Human IFN-gamma is expressed by mammalian cells, and is produced with raw materials of pharmaceutical applicable level. The host protein residue, nucleic acid residue and common pathogens are strictly controlled, and the production and quality management procedures of the product comply with GMP regulations to ensure the traceability of the production process and all raw materials.